An Extension Study of TAK-664 for Japanese People With Primary Immunodeficiency Disease
A Phase 3, Open-label, Non-controlled, Multi-dose, Extension Study to Evaluate the Long-term Safety and Tolerability of IGSC, 20% in Japanese Subjects With Primary Immunodeficiency Disease (PID)
Sponsor: Takeda
A PHASE3 clinical study on Primary Immunodeficiency Disease, this trial is completed. The trial is conducted by Takeda and has accumulated 13 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
13 versions recorded-
Feb 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Feb 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jun 2024 — Jul 2024 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jun 2023 — Jun 2024 [monthly]
Active Not Recruiting PHASE3
▶ Show 8 earlier versions
-
Feb 2023 — Jun 2023 [monthly]
Active Not Recruiting PHASE3
-
Feb 2022 — Feb 2023 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jan 2022 — Feb 2022 [monthly]
Recruiting PHASE3
-
Dec 2021 — Jan 2022 [monthly]
Recruiting PHASE3
-
Nov 2021 — Dec 2021 [monthly]
Recruiting PHASE3
-
Oct 2021 — Nov 2021 [monthly]
Recruiting PHASE3
-
Sep 2021 — Oct 2021 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
May 2021 — Sep 2021 [monthly]
Not Yet Recruiting PHASE3
First recorded
Apr 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Takeda
For direct contact, visit the study record on ClinicalTrials.gov .